ClinicalTrials.gg
RecruitingNCT07538843DAREUpdated Nov 16, 2026

An Observational Study Conducted in China to Evaluate the Efficacy and Safety of Darolutamide in Combination With Androgen Deprivation Therapy (ADT) for Men With Non-metastatic Prostate Cancer That Progressed Following Prior Bicalutamide + ADT Treatment

An observational study in Non-metastatic Castration-resistant Prostate Cancer, sponsored by Bayer. Recruiting at 1 site in China. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Bayer · Observational

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 3 months later.
Updated Nov 16, 2026Primary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
800
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 75 studies in Prostatic Neoplasms by Bayer — 11 open to participants now, 16 under way, 1 of them phase 3. Prostatic Neoplasms · Bayer.

Planned enrollment
20th of 40
800 · median 700
Started
2026
with 5 others
Observational
40 of 75
8 open now
Primary completion
2029-12
later than 12 of 15 live
Registered
73rd of 75
by date

Among the 75 studies in Prostatic Neoplasms by Bayer, this one is the 20th largest by planned enrollment of the 40 observational ones that give a count, is one of 6 that started in 2026, is one of 40 observational ones, reaches primary completion later than 12 of the 15 other live ones, and was the 73rd registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

11 of the 75 studies in Prostatic Neoplasms by Bayer are open now, in 12 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 75 studies in Prostatic Neoplasms by Bayer, or all of them as a file.
02

Study summary

In this observational study, participants receive darolutamide: a treatment that is already available for doctors to prescribe for non-metastatic castration-resistant prostate cancer (nmCRPC) or metastatic hormone-sensitive prostate cancer (mHSPC).

Prostate cancer is a common cancer in men, and the number of cases is rising, especially in China. Many men are diagnosed at a late stage, which makes treatment more difficult. Standard treatment for prostate cancer often includes lowering the levels of male hormones (androgens) in the body, as these hormones can help the cancer grow. This is called androgen deprivation therapy (ADT). Sometimes, medicines like bicalutamide are added to ADT, but over time, the cancer can become resistant to these treatments. When this happens and the cancer has not yet spread to other parts of the body, it is called nmCRPC. Newer agents, such as darolutamide, have demonstrated efficacy in controlling the disease and delaying progression, with a more favorable safety profile and fewer severe adverse events than conventional therapies.

This study wants to observe how effective darolutamide plus ADT is at controlling the cancer in Chinese men with nmCRPC who have already been treated with bicalutamide plus ADT during an earlier stage of their disease, known as non-metastatic hormone-sensitive prostate cancer (nmHSPC), but whose cancer has since progressed despite that treatment.

The study will look at how many participants have their prostate-specific antigen (PSA) levels drop to undetectable levels within 6 months of starting darolutamide (in the main group of 800 participants). PSA is a protein made by the prostate, and high levels can be a sign of prostate cancer. In a smaller group of 100 participants, the study will also look at how many men remain free from PSA progression (a sign that the cancer is not getting worse) after 12 months.

To learn more about the safety of darolutamide, the researchers will study whether the participants have adverse events. An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events that happen in studies, even if they do not think the adverse events might be related to the study treatments. The researchers will also learn more about how well darolutamide is working in these participants.

03

Conditions studied

  • Non-metastatic Castration-resistant Prostate Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Male patients diagnosed with nmCRPC, as determined by their treating physician, fulfilling the inclusion and exclusion criteria

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males Age ≥ 18 years.
  • (ECOG) performance status score of 0 or 1.
  • Patients receiving ≥6 m ADT+Bicalutamide in nmHSPC, progressed to nmCRPC judged by investigators.
  • Serum testosterone level\<1.7 nmol/L.
  • Decision to initiate treatment with ADT + Darolutamide as per investigator's routine treatment practice.
  • No evidence of as assessed by computed tomography (CT)/magnetic resonance imaging (MRI) for soft tissue disease and whole-body radionuclide bone scan for bone disease.
  • The form must be signed by the patient or his legal guardian (as applicable).
  • Patients who are fertile must use an effective method of during the study and must refrain from donating sperm during the study or for 3 months after the end of treatment, unless they have undergone a radical prostatectomy.

Exclusion criteria

Exclusion Criteria:

  • Participation in an program with interventions outside of routine clinical practice.
  • Presence of distant , including involvement of the Central Nervous System (CNS) and vertebral or meningeal involvement.
  • Symptomatic local or regional lesions requiring medical intervention (moderate or severe urinary tract obstruction or hydronephrosis caused by the primary tumor).
  • Previous treatment with 2nd-generation ARIs.
  • Previous treatment with CYP17 inhibitors.
  • Previous treatment with radiopharmaceuticals, immunotherapy, or other investigational treatment for nmCRPC.
  • Severe/unstable angina, myocardial infarction, symptomatic congestive heart failure, arterial or venous thromboembolic events, or ventricular arrhythmias.
  • Gastrointestinal diseases affecting absorption.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
800 participants (estimated)
Patient registry
No

Groups and cohorts

  • Master-cohort (6 months follow-up)

    Male patients receiving ADT+Bicalutamide for ≥ 6 months in non-metastatic hormone-sensitive prostate cancer (nmHSPC), that progressed to non-metastatic castration-resistant prostate cancer (nmCRPC)

    Drug: Darolutamide · Drug: ADT

  • Sub-cohort (12 months follow-up)

    Male patients receiving ADT+Bicalutamide for ≥ 6 months in non-metastatic hormone-sensitive prostate cancer (nmHSPC), that progressed to non-metastatic castration-resistant prostate cancer (nmCRPC)

    Drug: Darolutamide · Drug: ADT

Interventions

  • Darolutamide administered per local standard of care in combination with ADT.

    Also known as: Nubeqa, BAY1841788

  • DrugAntiandrogensStudies of AntiandrogensAntiandrogens pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Androgen deprivation therapy administered per local standard of care.

06

What researchers measure

Primary outcomes

  1. Proportion of patients with prostatic specific antigen (PSA) undetectable within 6 months (Master Cohort)

    The proportion of patients with undetectable PSA at any time within the 6 months after treatment initiation, undetectable PSA is defined as an absolute PSA level \<0.2 ng/ml

    Time frame: up to 6 months

  2. Proportion of patients with PSA Progression Free Survival (PSA-PFS) rate at 12 months (Sub-cohort)

    The proportion of patients who remain PSA progression free by 12 months. PSA progression: (i) PSA increase of≥ 25% and an absolute increase of≥2 ng/mL above the nadir, which is confirmed by a second value obtained 3 or more weeks later, in case of decline, or (ii) a PSA increase of≥25%, and an absolute increase of≥ 2 ng/mL after 12 weeks in case of no decline from the baseline.

    Time frame: up to 12 months

Secondary outcomes

  1. Proportion of patients with PSA50 within 3 months (Master cohort)

    The proportion of patients who achieve 50% or more decline from baseline PSA, at any time within 3 months of treatment initiation

    Time frame: Up to 3 months

  2. Proportion of patients with PSA50 within 6 months (Master cohort)

    The proportion of patients who achieve 50% or more decline from baseline PSA, at any time within 6 months of treatment initiation

    Time frame: Up to 6 months

  3. Proportion of patients with PSA90 within 3 months (Master cohort)

    The proportion of patients who achieve 90% or more decline from baseline PSA, at any time within 3 months of treatment initiation

    Time frame: Up to 3 months

  4. Proportion of patients with PSA90 within 6 months (Master cohort)

    The proportion of patients who achieve 90% or more decline from baseline PSA, at any time within 6 months of treatment initiation

    Time frame: Up to 6 months

  5. Proportion of patients with PSA undetectable within 3 months (Master cohort)

    The proportion of patients with undetectable PSA at any time within the 3 months of treatment initiation, undetectable PSA is defined as an absolute PSA level \<0.2 ng/ml

    Time frame: Up to 3 months

  6. Proportion of patients with PSA50/90 within 12 months (Sub-cohort)

    The proportion of patients who achieve 50%/90% or more decline from baseline PSA, at any time within the 12 months of treatment initiation

    Time frame: Up to 12 months

  7. Proportion of patients with PSA undetectable within 12 months (Sub-cohort)

    The proportion of patients with undetectable PSA at any time within the 12 months of treatment initiation, undetectable PSA is defined as an absolute PSA level \<0.2 ng/ml

    Time frame: Up to 12 months

  8. Metastasis-free survival (MFS) rate at 12 months (Sub-cohort)

    The proportion of patients who remain metastasis-free by 12 months. MFS is defined as time between the start of the first darolutamide treatment and evidence of metastasis (bone metastasis, visceral metastasis, distant lymph node metastasis) or death from any cause

    Time frame: Up to 12 months

  9. Proportion of patients with Treatment Emergent Adverse Events (Master and Sub-cohort)

    Frequency and severity according to CTCAE v.6, seriousness, causality and action taken related to darolutamide treatment

    Time frame: Up to 12 months

07

Study locations

1 of 1 sites recruiting
  • Many locations
    Multiple Locations, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — Currently, there is no established plan for the sharing of Individual Patient Data (IPD) from this study. The availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA 'Principles for responsible clinical trial data sharing.' This pertains to the scope, timepoint, and process of data access. As such, Bayer commits to considering requests from qualified researchers for patient- / study-level clinical trial data, and documents from clinical trials involving medicines and indications approved in the US and EU. However, this commitment does not reflect an active IPD sharing plan. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Researchers can use www.vivli.org to request access to IPD and documents from clinical studies to conduct research. Information on Bayer's criteria for listing studies is provided in the member section of the portal.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Dec 2029, 41 months after the start.

Of 109 industry-sponsored observational studies under Prostatic Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 65. This study's planned 41 months is close to that.

Counting every sponsor, half of 651 studies reached it within 60 months; a quarter within 28 and three quarters within 141.

Primary completion moved once since we started tracking on Sep 25, 2026: Nov 2029 → Dec 2029, on Nov 16, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 13, 2026
First posted
Apr 20, 2026
StartActual
Jul 31, 2026
Primary completionEst.
Dec 31, 2029was Nov 2029
CompletionEst.
Jan 30, 2030
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Nov 1, 2029→Dec 31, 2029
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Primary completion Nov 1, 2029→Dec 31, 2029
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07538843
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Apr 20, 2026
Start date
Jul 31, 2026
Primary completion
Dec 31, 2029 (estimated)
Completion
Jan 30, 2030 (estimated)
Last update
Nov 16, 2026

Study contacts

Bayer Clinical Trials Contact
Contact
clinical-trials-contact@bayer.com
18888422937

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion